Dimas Tadeu Covas

ORCID: 0000-0002-7364-2595
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Mesenchymal stem cell research
  • T-cell and Retrovirus Studies
  • CAR-T cell therapy research
  • Hemoglobinopathies and Related Disorders
  • Blood groups and transfusion
  • SARS-CoV-2 and COVID-19 Research
  • Virus-based gene therapy research
  • Animal Disease Management and Epidemiology
  • Immune Cell Function and Interaction
  • Viral Infectious Diseases and Gene Expression in Insects
  • Hematopoietic Stem Cell Transplantation
  • CRISPR and Genetic Engineering
  • Mosquito-borne diseases and control
  • Vector-Borne Animal Diseases
  • Parvovirus B19 Infection Studies
  • Erythrocyte Function and Pathophysiology
  • Tissue Engineering and Regenerative Medicine
  • Iron Metabolism and Disorders
  • Viral Infections and Vectors
  • Pluripotent Stem Cells Research
  • Immunotherapy and Immune Responses
  • RNA Interference and Gene Delivery
  • Cancer Cells and Metastasis
  • Chronic Myeloid Leukemia Treatments
  • Hemophilia Treatment and Research

Universidade de São Paulo
2016-2025

Instituto Butantan
2019-2024

Universidade de Ribeirão Preto
2015-2024

Clinics Hospital of Ribeirão Preto
2015-2024

Fundação Hemopa
2009-2024

Fundação de Medicina Tropical
2024

Fundação Oswaldo Cruz
1999-2024

Universidade Federal de Minas Gerais
2024

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2017-2024

Universidade Federal de São Paulo
2004-2022

BackgroundButantan–Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine against dengue disease, but data on its overall efficacy are needed.MethodsIn ongoing phase 3, double-blind trial in Brazil, we randomly assigned participants to receive Butantan-DV or placebo, with stratification according age (2 6 years, 7 17 and 18 59 years); 5 years of follow-up planned. The objectives the were evaluate symptomatic, virologically confirmed any...

10.1056/nejmoa2301790 article EN New England Journal of Medicine 2024-01-31

Mesenchymal stem cells (MSCs) give origin to the marrow stromal environment that supports hematopoiesis. These present a wide range of differentiation potentials and complex relationship with hematopoietic (HSCs) endothelial cells. In addition bone (BM), MSCs can be obtained from other sites in adult or fetus. We isolate umbilical cord (UC) veins are morphologically immunophenotpically similar BM. culture, these capable differentiating vitro into adipocytes, osteoblasts, condrocytes. The...

10.1634/stemcells.2004-0024 article EN Stem Cells 2004-12-01

Mesenchymal stem cells (MSCs) are multipotent precursors present in adult bone marrow, that differentiate into osteoblasts, adipocytes and myoblasts, play important roles hematopoiesis. We examined gene expression of these by serial analysis expression, found collagen I, secreted protein acidic rich cysteine (osteonectin), transforming growth factor beta- (TGF-β) induced, cofilin, galectin-1, laminin-receptor 1, cyclophilin A, matrix metalloproteinase-2 among the most abundantly expressed...

10.1634/stemcells.21-6-661 article EN Stem Cells 2003-11-01

Bone marrow contains a population of stem cells that can support hematopoiesis and differentiate into different cell lines including adipocytes, osteocytes, chondrocytes, myocytes, astrocytes, tenocytes. These have been denoted mesenchymal cells. In the present study we isolated derived from endothelium subendothelium umbilical cord vein which possesses morphological, immunophenotypical differentiation characteristics similar to those bone marrow. The were three cords after treatment lumen...

10.1590/s0100-879x2003000900006 article EN cc-by Brazilian Journal of Medical and Biological Research 2003-09-01

Autologous hematopoietic stem cell transplantation (AHSCT) increases C-peptide levels and induces insulin-independence in patients with type 1 diabetes. This study aimed to investigate how clinical outcomes may associate the immunological status, especially concerning balance between immunoregulation autoreactivity. Twenty-one diabetes were monitored after AHSCT, assessed every six months for duration of insulin independence, levels, frequencies islet-specific autoreactive CD8+ T-cells,...

10.3389/fimmu.2017.00167 article EN cc-by Frontiers in Immunology 2017-02-22

To evaluate the immunological mechanisms associated with clinical outcomes after autologous hematopoietic stem cell transplantation (AHSCT), focusing on regulatory T- (Treg) and B- (Breg) immune reconstitution, 31 systemic sclerosis (SSc) patients underwent simultaneous evaluations over 36-month posttransplantation follow-up. Patients were retrospectively grouped into responders (n = 25) nonresponders 6), according to response AHSCT. Thymic function B-cell neogenesis respectively assessed by...

10.1182/bloodadvances.2017011072 article EN cc-by-nc-nd Blood Advances 2018-01-17

Abstract The coronavirus disease 2019 (COVID-19) epidemic in Brazil was driven mainly by the spread of Gamma (P.1), a locally emerged variant concern (VOC) that first detected early January 2021. This estimated to be responsible for more than 96 per cent cases reported between and June 2021, being associated with increased transmissibility severity, reduction neutralization antibodies effectiveness treatments or vaccines, diagnostic detection failure. Here we show that, following several...

10.1093/ve/veac024 article EN cc-by-nc Virus Evolution 2022-01-01

Anemia, neutropenia, and thrombocytopenia are commonly observed in HIV-infected patients. This study was undertaken to evaluate the prevalence of cytopenias their association with CD4 count. Furthermore, hemoglobin concentration mortality also investigated.We reviewed data 701 patients followed at our institution. Blood cell counts, concentration, count, viral load were recorded. We recorded rate after 1 year groups <200/μl ≥ 200/μl according concentration.Of total patients, 37.5% had...

10.1016/j.ijid.2011.08.001 article EN publisher-specific-oa International Journal of Infectious Diseases 2011-08-31

Interference by autofluorescence is one of the major concerns immunofluorescence analysis in situ hybridization-based diagnostic assays. We present a useful technique that reduces autofluorescent background without affecting tissue integrity or direct signals brain sections. Using six different protocols, such as ammonia/ethanol, Sudan Black B (SBB) 70% ethanol, photobleaching with UV light and combinations them both formalin-fixed paraffin-embedded frozen human sections, we have found...

10.14670/hh-25.1017 article EN PubMed 2010-08-01

Mesenchymal stem/stromal cells (MSC) are being widely explored as promising candidates for cell-based therapies. Among the different human MSC origins exploited, umbilical cord represents an attractive and readily available source of that involves a non-invasive collection procedure. In order to achieve relevant cell numbers clinical applications, it is crucial develop scalable culture systems allow bioprocess control monitoring, combined with use serum/xenogeneic (xeno)-free media. present...

10.1002/biot.201500532 article EN Biotechnology Journal 2016-05-11

Magnetic hyperthermia (MHT) has been shown as a promising alternative therapy for glioblastoma (GBM) treatment. This study consists of three parts: The first part evaluates the heating potential aminosilane-coated superparamagnetic iron oxide nanoparticles (SPIONa). second and third parts comprise evaluation MHT multiple applications in GBM model, either vitro or vivo. obtained curves SPIONa (100 nm, +20 mV) their specific absorption rates (SAR) stablished best therapeutic conditions...

10.3390/ijms21030958 article EN International Journal of Molecular Sciences 2020-01-31

To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients COVID-19 who were within 10 days of initial symptom onset eligible. the CCP group received 3 daily doses (600 mL/d) addition to standard treatment; control treatment only. Primary outcomes death rates at 30 and 60 study randomization. Secondary ventilator-free hospital-free days. We enrolled...

10.3201/eid2803.212299 article EN cc-by Emerging infectious diseases 2022-01-31
Coming Soon ...